WAUKEGAN, Ill.--(BUSINESS WIRE)--April 26, 2006--NeoPharm, Inc. (Nasdaq:NEOL - News) today announced that the use of a novel software-based catheter planning and positioning system developed by BrainLAB AG may optimize the efficacy and safety of tumor targeting therapies delivered via Convection Enhanced Delivery (CED), specifically cintredekin besudotox (IL13-PE38QQRR), an investigational treatment being studied for the treatment of patients with first recurrent glioblastoma multiforme.
